NASDAQ:ASMB
Assembly Biosciences, Inc.
Assembly Biosciences, Inc.'s revenue grew 153.5% in fiscal 2025 to $72.3M while operating margin rose to −16.8%, its highest in 3 years. Free cash flow was −$41.2M, −56.9% of revenue, and the diluted share count rose 86.7%.Summary generated from Assembly Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$72.3M
Revenue growth+153.5%
Revenue, 5-yr CAGR−1.8%
Gross marginn/a
Operating margin−16.8%
Net margin−8.5%
ROICn/a
Return on equity−5.1%
Debt / equityn/a
Free cash flow−$41.2M
FCF margin−56.9%
Share count change+86.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 6 | 0 | 7 | 29 | 72 |
| Operating income | −133 | −94 | −65 | −45 | −12 |
| Net income | −130 | −93 | −61 | −40 | −6 |
| Free cash flow | −96 | −85 | 22 | −51 | −41 |
Recent filings
- 8-K/AAmended results of operations and financial condition
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KCompletion of an acquisition or disposition
Aug 13, 2026 - 4Insider transaction report
Jun 18, 2026 - 4Insider transaction report
Jun 5, 2026 - 8-KDirector or officer change
Jun 5, 2026 - 8-KEntry into a material agreement
May 26, 2026 - 8-KRegulation FD disclosure
May 22, 2026